| P2093 | author name string | S Hirohashi | |
| | T Shibata | |
| | S Kasai | |
| | T Kosuge | |
| | N Hiraoka | |
| | H Ojima | |
| | M Iwasaki | |
| | D Yoshikawa | |
| P2860 | cites work | Long-term survival and prognostic factors in the surgical treatment for intrahepatic cholangiocarcinoma | Q75233624 |
| | Does gross appearance indicate prognosis in intrahepatic cholangiocarcinoma? | Q77658457 |
| | Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas | Q78204868 |
| | Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study | Q79835026 |
| | Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance | Q82499254 |
| | Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors | Q24535796 |
| | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 |
| | Untangling the ErbB signalling network | Q27860884 |
| | Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 |
| | The ErbB signaling network: receptor heterodimerization in development and cancer | Q29617919 |
| | Histologic risk factors and clinical outcome in colorectal malignant polyp: a pooled-data analysis | Q30991450 |
| | Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. | Q33237214 |
| | Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report | Q33250432 |
| | Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy | Q33984809 |
| | Cholangiocarcinoma. | Q33990595 |
| | Phase II study of erlotinib in patients with advanced biliary cancer | Q33997258 |
| | Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators | Q34221643 |
| | EGFR and cancer prognosis | Q34399312 |
| | Development and differentiation of bile ducts in the mammalian liver | Q34450305 |
| | Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma | Q34570747 |
| | Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution | Q34578979 |
| | Prognostic factors in node-negative intrahepatic cholangiocarcinoma with special reference to angiogenesis | Q35711843 |
| | Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma | Q35761590 |
| | Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. | Q36584970 |
| | Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis | Q36610236 |
| | Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature | Q36614453 |
| | The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. | Q36765297 |
| | ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions | Q38455863 |
| | Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry | Q38456543 |
| | Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells | Q40497486 |
| | International variations in epidemiology of cancers of the extrahepatic biliary tract | Q41374232 |
| | Angiogenesis and tumor metastasis | Q41724143 |
| | Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival | Q44524740 |
| | Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers | Q46488823 |
| | Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas | Q46609599 |
| | c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. | Q52122642 |
| | Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. | Q53394493 |
| | Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver. | Q53496139 |
| | Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours | Q57003964 |
| | Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours | Q69856767 |
| | Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis | Q73507842 |
| | Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma | Q73653633 |
| | Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis | Q74114483 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cholangiocarcinoma | Q124292 |
| P304 | page(s) | 418-425 | |
| P577 | publication date | 2007-12-18 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma | |
| P478 | volume | 98 | |